Released May 2, 2019, after the close
10-Q filed May 7, 2019, 37 days after period end · 0001162194-19-000033
Q1 2019 · 10-Q
Revenue$30.11M$30.11M +19.3% vs Q1 2018−6.8% vs Q4 2018
Net Income-$25.47M-$25.47M N/M vs Q1 2018N/M vs Q4 2018
EPS Diluted-$0.44-$0.44 N/M vs Q1 2018N/M vs Q4 2018
Gross Profit$16,990,000+26.5%
Operating Income-$14,206,000N/M
Operating Cash Flow-$20,130,000N/M
Free Cash Flowderived-$20,396,000N/M
Margins · derived
Gross margin56.4%+3.2 pt vs Q1 2018
Operating margin-47.2%+2.9 pt vs Q1 2018
Net margin-84.6%−32.1 pt vs Q1 2018
What the release said
The release
Same quarter
| Metric | Q1 2019 | Q1 2018 | Q1 2017 | Q1 2016 |
|---|---|---|---|---|
| Revenue | $30.11M | $25.25M | $25.53M | $29.00M |
| Net Income | -$25.47M | -$13.25M | -$17.20M | -$19.88M |
| EPS Diluted | -$0.44 | -$0.34 | -$0.59 | -$0.69 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR